Opinion

Video

Closing Thoughts About IgA Nephropathy Treatment

Panelists discuss how the management of immunoglobulin A (IgA) nephropathy is undergoing a transformative shift from symptom control to targeted disease modification, with emerging therapies offering new hope for patients while requiring thoughtful integration into clinical practice and health care systems.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Sheela Rao
4 experts are featured in this series.
5 experts in this video
4 experts are featured in this series.
5 experts in this video
5 experts are featured in this series
5 experts are featured in this series
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo